Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS
News May 19, 2010
Acorda Therapeutics, Inc. has announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases.
Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award was presented at the 2010 NORD Partners in Progress Gala in Washington, D.C.
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments.”
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. ”NORD is also an invaluable resource for people affected by rare diseases, providing information, education and support services to patients, families, medical professionals, and the public. We are honored to be recognized by an organization that has made such important contributions to medicine and society.”
“Multiple sclerosis is a progressive disease with devastating health consequences, and new treatment options are needed to improve the lives of people with MS,” said Peter L. Saltonstall, President and CEO of NORD. “We commend Acorda for its commitment to bringing novel therapies to market for people with MS and other neurological diseases.”
In the United States, a disease is considered rare if it affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 such diseases. Although MS is now estimated to affect between 400,000-500,000 Americans, it was classified as a rare disease at the time that Acorda began developing AMPRYA.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Comments | 1 ADD COMMENT
Gail Holy | Apr 10, 2018
As a sign of gratitude for how my son was cured from autism, i decided to reach out to those still suffering from Autism spectrum. My son suffered autism for 7 years and 4 months, it was really tough and heartbreaking for me because he was my all and the symptoms were terrible, he always have difficulty with communication not verbal, and he always complain of poor eye contact, hurt his self, likes music so much. We tried various therapies prescribed by our neurologist but none could cure him. Not until a day when I searched for a cure online and i saw different testimonies of how people are thanking and praising Dr Alwan who has cured their autistic children and so many others with Fallopian tube blockage, infections and diseases problems, and they all left the email of the doctor who had the cure to autism . I never imagined autism has a natural cure but i have no other choice than to contact Dr Alwan and he assured me my son will be fine and then asked me to purchase his autism herbs which i did. Few days later I got the herbal medication he recommended and also gave me instructions and guild lines on how it used. Behold it was amazing, before 2 weeks time i began to see different changes on my son now is perfectly okay, even up till this moment he is so full of life. Autism has a cure and it is an herbal cure contact the doctor for more info on (firstname.lastname@example.org) on how to get cured of your autistic child. Thanks for reading my testimony.
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018